iCAD to Participate in the iAccess Alpha Buyside Best Ideas Fall Conference 2024
iCAD, a leader in AI-powered breast health solutions, announced its participation in the iAccess Alpha Buyside Best Ideas Fall Conference 2024. The event is scheduled for September 24-25, 2024. Key highlights include:
• CEO Dana Brown and CFO Eric Lonnqvist will deliver a company presentation on September 24 at 11:00 am ET.
• One-on-one meetings will be hosted on September 25.
• The presentation will be webcast live and available for replay.
• Interested parties can register and schedule meetings through the conference website.
This event provides an opportunity for investors to gain insights into iCAD's mission to create a world where cancer can't hide using clinically proven AI technology.
iCAD, leader nelle soluzioni per la salute del seno basate sull'intelligenza artificiale, ha annunciato la sua partecipazione alla iAccess Alpha Buyside Best Ideas Fall Conference 2024. L'evento è previsto per 24-25 settembre 2024. I punti salienti includono:
• Il CEO Dana Brown e il CFO Eric Lonnqvist terranno una presentazione aziendale il 24 settembre alle 11:00 ET.
• Incontri one-on-one saranno organizzati il 25 settembre.
• La presentazione sarà trasmessa in diretta e disponibile per la visione successiva.
• I soggetti interessati possono registrarsi e programmare incontri tramite il sito web della conferenza.
Questo evento rappresenta un'opportunità per gli investitori di ottenere informazioni sulla missione di iCAD di creare un mondo in cui il cancro non può nascondersi, utilizzando tecnologie AI clinicamente provate.
iCAD, líder en soluciones de salud mamaria impulsadas por inteligencia artificial, anunció su participación en la iAccess Alpha Buyside Best Ideas Fall Conference 2024. El evento está programado para el 24 y 25 de septiembre de 2024. Los puntos destacados incluyen:
• La CEO Dana Brown y el CFO Eric Lonnqvist ofrecerán una presentación de la empresa el 24 de septiembre a las 11:00 am ET.
• Se llevarán a cabo reuniones uno a uno el 25 de septiembre.
• La presentación será transmitida en vivo y estará disponible para repetición.
• Las partes interesadas pueden registrarse y programar reuniones a través del sitio web de la conferencia.
Este evento ofrece la oportunidad a los inversores de conocer la misión de iCAD de crear un mundo donde el cáncer no pueda esconderse utilizando tecnología de IA clínicamente probada.
iCAD, AI 기반 유방 건강 솔루션의 선두주자, iAccess Alpha Buyside Best Ideas Fall Conference 2024에 참여한다고 발표했습니다. 이 행사는 2024년 9월 24-25일로 예정되어 있습니다. 주요 하이라이트는 다음과 같습니다:
• CEO 다나 브라운과 CFO 에릭 론크비스트가 9월 24일 오전 11:00 ET에 회사 프레젠테이션을 진행합니다.
• 9월 25일에 일대일 미팅이 개최됩니다.
• 프레젠테이션은 생중계될 것이며 다시 볼 수 있습니다.
• 관심 있는 분들은 컨퍼런스 웹사이트를 통해 등록하고 미팅을 예약할 수 있습니다.
이번 행사는 투자자들이 iCAD이 임상적으로 입증된 AI 기술을 사용하여 암이 숨을 수 없는 세상을 만드는 사명에 대한 통찰을 얻을 수 있는 기회를 제공합니다.
iCAD, leader dans les solutions de santé mammaire propulsées par l'intelligence artificielle, a annoncé sa participation à la iAccess Alpha Buyside Best Ideas Fall Conference 2024. L'événement est prévu pour le 24 et 25 septembre 2024. Les points forts incluent :
• La PDG Dana Brown et le CFO Eric Lonnqvist présenteront l'entreprise le 24 septembre à 11h00 ET.
• Des réunions individuelles seront organisées le 25 septembre.
• La présentation sera diluée en direct et disponible en replay.
• Les parties intéressées peuvent s'inscrire et planifier des réunions via le site Web de la conférence.
Cet événement offre une occasion aux investisseurs d'obtenir des informations sur la mission d'iCAD de créer un monde où le cancer ne peut pas se cacher, en utilisant une technologie d'IA cliniquement prouvée.
iCAD, führend in KI-gestützten Lösungen für die Brustgesundheit, hat seine Teilnahme an der iAccess Alpha Buyside Best Ideas Fall Conference 2024 angekündigt. Die Veranstaltung findet am 24. und 25. September 2024 statt. Die Highlights sind:
• CEO Dana Brown und CFO Eric Lonnqvist werden am 24. September um 11:00 Uhr ET eine Unternehmenspräsentation halten.
• Einzelgespräche finden am 25. September statt.
• Die Präsentation wird live übertragen und ist anschließend verfügbar.
• Interessierte können sich registrieren und Meetings über die Konferenz-Website planen.
Diese Veranstaltung bietet Investoren die Möglichkeit, Einblicke in die Mission von iCAD zu gewinnen, eine Welt zu schaffen, in der Krebs sich nicht verstecken kann, mithilfe klinisch erprobter KI-Technologie.
- None.
- None.
NASHUA, N.H., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the iAccess Alpha Buyside Best Ideas Fall Conference 2024 on September 24 and 25, 2024. CEO, Dana Brown and CFO, Eric Lonnqvist will deliver a company presentation at 11:00 am ET on September 24, and host one-on-one meetings the following day, September 25.
To learn more about the iAccess Alpha Buyside Best Ideas Fall Conference 2024, or to register and schedule a one-on-one meeting with iCAD, please visit the conference website at https://www.iaccessalpha.com/home.
The iCAD presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/3064/51217. The iCAD presentation will also be available on the company’s investor relations website under the Events & Earnings Calls tab.
About iAccess Alpha
iAccess Alpha hosts virtual investor conferences, where presenting companies are recommended by investors. The conference format spans two days, with company webcast presentations on day one, followed by one-on-one meetings with company management teams on day two.
About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly
Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
CONTACTS
Media inquiries:
pr@icadmed.com
Investor Inquiries:
John Nesbett/Rosalyn Christian
IMS Investor Relations
icad@imsinvestorrelations.com
FAQ
When is iCAD (ICAD) participating in the iAccess Alpha Buyside Best Ideas Fall Conference 2024?
Who will be presenting for iCAD (ICAD) at the iAccess Alpha conference?
What time is iCAD's (ICAD) presentation at the iAccess Alpha conference?
Will iCAD's (ICAD) presentation at the iAccess Alpha conference be available online?
How can investors schedule a one-on-one meeting with iCAD (ICAD) at the iAccess Alpha conference?
